JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB23698

Anti-EDG2 /LPA-1 antibody

5

(2 Reviews)

|

(19 Publications)

Rabbit Polyclonal EDG2 /LPA-1 antibody. Suitable for WB and reacts with Rat, Human, Mouse samples. Cited in 19 publications.

View Alternative Names

EDG2, LPA1, LPAR1, Lysophosphatidic acid receptor 1, LPA receptor 1, LPA-1, Lysophosphatidic acid receptor Edg-2

2 Images
Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)
  • WB

Supplier Data

Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)

All lanes:

Western blot - Anti-EDG2 /LPA-1 antibody (ab23698)

Lane 1:

Solubilised Mouse Liver at 50 µg

Lane 2:

A549 Cell Lysate at 40 µg

Lane 3:

Rat liver lysate at 40 µg

Predicted band size: 41 kDa

false

Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)
  • WB

CiteAb

Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)

EDG2 /LPA-1 western blot using anti-EDG2 /LPA-1 antibody ab23698. Publication image and figure legend from Wang, H., Tu, S., et al., 2019, Evid Based Complement Alternat Med, PubMed 31781264.

ab23698 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab23698 please see the product overview.

Berberine alters the expression levels of K-ras and c-Raf, as well as the phosphorylation levels of ERK1/2 and p-38 of FLS-RA. (a, b) Berberine treatment at 12.5 and 25 μM for 24 h downregulates the expression of K-ras and ATX, as detected by RT-PCR. (c) Berberine makes no difference to the expression of LPA1, as measured by western blot. (d) The expression levels of c-Raf, P-p38, P-JNK, and P-ERK1/2 are measured through western blot. Berberine treatment for 24 h downregulates the expression of P-p38 (e), P-ERK1/2 (f), and c-Raf (h) in a dose-dependent manner. (g) The phosphorylation level of JNK shows no significant difference before and after berberine treatment. *p < 0.05; ***p < 0.001. Ctrl, control group; ATX, autotaxin; and FLS-RA, fibroblast-like synovial cells of rheumatoid arthritis.

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/200", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/200", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/200", "WB-species-notes": "<p></p>" }, "Xenopus laevis": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 Preservative: 0.02% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EDG2 also known as LPA-1 LPAR1 or lysophosphatidic acid receptor 1 acts as a receptor for LPA (lysophosphatidic acid) a bioactive lipid mediator. This protein has a molecular mass of approximately 41 kDa. It is part of the G protein-coupled receptor (GPCR) family. EDG2 is mainly expressed in organs such as the brain heart and lungs. It plays an important role in cellular signal transduction by binding LPA which leads to various cellular responses.
Biological function summary

EDG2/LPA-1 influences several cellular processes including cell proliferation migration and survival. It does not function as part of a larger complex; instead it activates intracellular signaling cascades upon LPA binding. This activation leads to downstream effects that regulate processes like cytoskeletal reorganization and gene expression. Its influence extends to immune response modulation making it significant in understanding cellular behavior and communication.

Pathways

EDG2/LPA-1 is important in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K/AKT) signaling pathways. These pathways affect cell growth survival and metabolism showcasing the receptor's importance in cellular regulation. Through these pathways EDG2 interacts with multiple proteins including RAC1 a small GTPase involved in cytoskeletal organization and various kinase enzymes that facilitate signal transduction.

EDG2/LPA-1 has associations with cancer and fibrosis. In cancer the receptor influences tumor growth and metastasis due to its role in cell migration and proliferation. It connects to the matrix metalloproteinases (MMPs) in this context which degrade extracellular matrix components to facilitate cancer cell invasion. Additionally in fibrotic diseases EDG2's influence on fibroblast activity leads to tissue scarring and dysfunctional repair. Understanding these connections helps to explore therapeutic targets meant to modulate EDG2/LPA-1 activity in pathological conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor for lysophosphatidic acid (LPA) (PubMed : 19306925, PubMed : 25025571, PubMed : 26091040, PubMed : 9070858). Plays a role in the reorganization of the actin cytoskeleton, cell migration, differentiation and proliferation, and thereby contributes to the responses to tissue damage and infectious agents. Activates downstream signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Signaling inhibits adenylyl cyclase activity and decreases cellular cAMP levels (PubMed : 26091040). Signaling triggers an increase of cytoplasmic Ca(2+) levels (PubMed : 19656035, PubMed : 19733258, PubMed : 26091040). Activates RALA; this leads to the activation of phospholipase C (PLC) and the formation of inositol 1,4,5-trisphosphate (PubMed : 19306925). Signaling mediates activation of down-stream MAP kinases (By similarity). Contributes to the regulation of cell shape. Promotes Rho-dependent reorganization of the actin cytoskeleton in neuronal cells and neurite retraction (PubMed : 26091040). Promotes the activation of Rho and the formation of actin stress fibers (PubMed : 26091040). Promotes formation of lamellipodia at the leading edge of migrating cells via activation of RAC1 (By similarity). Through its function as LPA receptor, plays a role in chemotaxis and cell migration, including responses to injury and wounding (PubMed : 18066075, PubMed : 19656035, PubMed : 19733258). Plays a role in triggering inflammation in response to bacterial lipopolysaccharide (LPS) via its interaction with CD14. Promotes cell proliferation in response to LPA (By similarity). Inhibits the intracellular ciliogenesis pathway in response to LPA and through AKT1 activation (PubMed : 31204173). Required for normal skeleton development. May play a role in osteoblast differentiation. Required for normal brain development. Required for normal proliferation, survival and maturation of newly formed neurons in the adult dentate gyrus. Plays a role in pain perception and in the initiation of neuropathic pain (By similarity).
See full target information LPAR1

Publications (19)

Recent publications for all applications. Explore the full list and refine your search

Cells 13: PubMed38995003

2024

Hypoxia Promotes Invadosome Formation by Lung Fibroblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Mégane Lebel,Dominic O Cliche,Martine Charbonneau,Karine Brochu-Gaudreau,Damien Adam,Emmanuelle Brochiero,Claire M Dubois,André M Cantin

Glia 71:945-956 PubMed36495059

2022

Schwann cell stimulation induces functional and structural changes in peripheral nerves.

Applications

Unspecified application

Species

Unspecified reactive species

Cosmin I Ciotu,Katrin Kistner,Ulrich Kaindl,Flavia Millesi,Tamara Weiss,Christine Radtke,Andreas Kremer,Katy Schmidt,Michael J M Fischer

Biomolecules 12: PubMed36551233

2022

Alteration of Cellular Energy Metabolism through LPAR2-Axin2 Axis in Gastric Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hosne Ara,Utsab Subedi,Papori Sharma,Susmita Bhattarai,Sudha Sharma,Shrivats Manikandan,Xiuping Yu,Md Shenuarin Bhuiyan,Hong Sun,Sumitra Miriyala,Manikandan Panchatcharam

International journal of molecular sciences 23: PubMed36142408

2022

Lysophosphatidic Acid Promotes Epithelial-Mesenchymal Transition in Kidney Epithelial Cells via the LPAR1/MAPK-AKT/KLF5 Signaling Pathway in Diabetic Nephropathy.

Applications

Unspecified application

Species

Unspecified reactive species

Geon-Ho Lee,Jayeon Cheon,Donghee Kim,Hee-Sook Jun

ASN neuro 14:17590914221083203 PubMed35593118

2022

Astrocyte Cell Surface Antigen 2 and Other Potential Cell Surface Markers of Enteric glia in the Mouse Colon.

Applications

Unspecified application

Species

Unspecified reactive species

Vladimir Grubišić,Brian D Gulbransen

The Journal of clinical investigation 132: PubMed35166239

2022

LPAR1 regulates enteric nervous system function through glial signaling and contributes to chronic intestinal pseudo-obstruction.

Applications

Unspecified application

Species

Unspecified reactive species

Mohammad M Ahmadzai,Jonathon L McClain,Christine Dharshika,Luisa Seguella,Fiorella Giancola,Roberto De Giorgio,Brian D Gulbransen

Molecules (Basel, Switzerland) 26: PubMed34684879

2021

Effect of the Gintonin-Enriched Fraction on Glucagon-Like-Protein-1 Release.

Applications

Unspecified application

Species

Unspecified reactive species

Rami Lee,Sun-Hye Choi,Han-Sung Cho,Hongik Hwang,Hyewhon Rhim,Hyoung-Chun Kim,Sung-Hee Hwang,Seung-Yeol Nah

International journal of molecular sciences 22: PubMed34639115

2021

Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1/ROCK2/PI3K/AKT Signaling Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Donghee Kim,Hyo-Jin Kim,Jin-Ok Baek,Joo-Young Roh,Hee-Sook Jun

Evidence-based complementary and alternative medic 2019:2580207 PubMed31781264

2019

Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA.

Applications

Unspecified application

Species

Unspecified reactive species

Hui Wang,Shenghao Tu,Sisi Yang,Pan Shen,Yao Huang,Xin Ba,Weiji Lin,Ying Huang,Yu Wang,Kai Qin,Zhe Chen

Therapeutic advances in medical oncology 11:1758835919875319 PubMed31692673

2019

microRNA-329 reduces bone cancer pain through the LPAR1-dependent LPAR1/ERK signal transduction pathway in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Xian-Ping Wu,Yan-Ping Yang,Rui-Xuan She,Zu-Min Xing,Han-Wen Chen,Yi-Wen Zhang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com